2017

May 2017

VERSÉA Conceptualized

  • Founders enter & conduct due diligence within the pharmaceutical Alt-Therapies market

OCTOBER 2017

Thought Leaders Developed

  • Initial introduction for the company mission with Key Opinion Leaders (KOLs) and pharmaceutical executives in the pain and CNS specialties
[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2018

MARCH 2018

VERSÉA Founded

  • In 2018 after founders exited a public sale in the medical space Verséa was formed.  

July 2018

Off We Go!

  • Core executive leadership team expands to 6 and founders capital vested.

OCTOBER 2018

Medical Team Expands!

  • Medical Director and Physician Advisors Sign On

DECEMEBER 2018

Brand Launch

  • Soft launch of company & products at medical conferences 
[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2019

February 2019

Clinical Research Begins

  • Completes 2 IRB studies accepted for medical publication

May 2019

Team Expansion

  • Clinical and regulatory experts join
  • Core management team expands to 9
  • Medical advisory team to 14

October 2019

Commercial Product Offerd in 30+ States

  • Verséa Diagnostic’s Division Formed

December 2019

Custom CRM and Sales System Buildout Complete

  • Verséa releases its own customized software solution to help manage: products, sales, distribution for master distributors, hcps and consumers with ordering and fulfillment.
[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2020

March 2020

Vertical Expansion

  • 4+ NIH grant submissions
  • Operations expansion globally into EAU and FDA Diagnostics
  • Versea aligns with expanded customer base to include urgent care groups, major hospitals and surgery centers (ASC’s) nationally

June 2020

Portfolio Expansion

  • 25+ medical doctors sign MSA and take on clinical and commercial advisory roles
  • GPO’s, Ex US expansion, Telehealth & large partnerships executed for scalability

September 2020

First in USA!

  • Verséa and its research partner, VitaMed Research, achieves 1st in the United States HIPPA Compliant IRB Approved, Patient Registry.
  • Research study quickly enrolls 300+  Patients completing INH survey month to month on Verséa  products
[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

We'll Ensure You Always Get the Best Results With VERSÉA

VERSÉA always will test, research, develop, and improve products and services to make them better, safer, more accessible for healthcare providers and patients.

High-End Technology

HIPPA + FDA Compliant Systems and Products

Effective Therapies

Leveraging all VERSÉA Products + Verticles

Safe Products

Adhering to EUA and FDA Quality

HealthCare Provider Driven

HealthCare Providers are at the Core of the VERSÉA Brand

From your initial phone call or inquiry placed through our website(s), you will notice the Verséa difference. We offer direct access to industry-leading medial professionals and products. Our products and services will be tailored to best fit your needs of your practice and the needs of your practice.